When building your watch list, look for stocks with an 80 or higher RS Rating. AnaptysBio now meets that criteria, with an increase from 72 to 81 Wednesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating of over 80 as they begin their biggest climbs.
While AnaptysBio is not near an ideal buy zone right now, see if it is able to form and break out of a proper consolidation.
The company reported 0% earnings growth last quarter. Sales rose 287%.
AnaptysBio earns the No. 129 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
